Cosmo Pharmaceuticals (COPN) Investor Day 2025 summary

Strategic vision and business model

• Announced an ambitious 2030 vision to become the most innovative force in life sciences, empowering patients and professionals through science and technology.

• Focused on gut, skin, and AI-driven MedTech, targeting high-growth markets with a €222B TAM by 2030 and CAGRs up to 39%.

• Business structured into MedTechAI, dermatology, gastroenterology, and CDMO, leveraging AI and partnerships with Medtronic, NVIDIA, Apple, and others.

• Strategic clarity achieved by divesting non-core assets and prioritizing core areas, with a strong balance sheet and no debt supporting organic and inorganic growth.

• AI is positioned as a strategic engine, integrating digital health, real-world data, and early intervention.

Financial guidance and growth outlook

• Recurring revenue CAGR projected at 23% for the existing portfolio, rising to 39% with new launches, targeting €480M by 2030.

• EBITDA margin expected to expand from low single digits or 19% to 40% by 2030, driven by new products and margin transformation.

• 2024 recurring revenue guidance set at $85–90 million, with significant R&D investment impacting near-term margins.

• Capital allocation remains disciplined, prioritizing R&D, strategic partnerships, and shareholder returns, aiming for above 4x return.

• Strong balance sheet with significant cash position supports organic growth, R&D, and shareholder dividends.

Pipeline and business developments

• Winlevi is the #1 branded topical acne prescription in the US, expanding to 40 countries by 2027.

• Breezula (clascoterone) for androgenetic alopecia completed Phase 3 enrollment, with US commercialization targeted for 2027–2028 and results expected in fall 2025.

• MedTechAI (GI Genius) platform scaled globally, now in 28 countries and over 4M patients, expanding into upper GI, Barrett’s esophagus, and integrating with Apple Vision Pro.

• Pipeline includes first-in-class or first-in-label treatments for bile acid diarrhea and distal ulcerative colitis, with clinical trials underway and results expected in 2025.

• Digital health strategy includes launching AI-powered digital companions for hair loss and other chronic, data-rich conditions, with digital/telehealth channels driving patient engagement.